Emisphere Technologies

Emisphere Technologies has appointed Michael V. Novinski to the position of president and chief executive officer effective immediately. Mr. Novinski had previously served as  president of Organon USA Inc., a business unit of Organon BioSciences, for the last four years. During that tenure, Organon USA received FDA approval for a number of ethical pharmaceutical products in the areas of Women’s Healthcare, Fertility, Neuroscience, Anti-thrombotics and Anesthesia.

Mr. Novinski replaces Lewis Bender, who was appointed interim chief executive officer on January 16, 2007. He has more than 28 years of industry and specialty product experience, which is critical to Emisphere as it moves to late stage product development. Mr. Novinski held several senior executive positions within Organon BioSciences prior to his recent role at Organon USA. On March 12, 2007, Akzo Nobel announced the intended sale of Organon BioSciences to Schering-Plough for $14.4 Billion in cash.

“I am very excited about this opportunity to join Emisphere,” said Mr. Novinski. “The company’s technology is exciting and well advanced and I believe that it will yield important improvements in healthcare. Many key Emisphere programs have the potential to create brands with substantial value and unique profiles and benefits for both prescribers and patients.”